Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

Ozempic-style drugs prove to be 'a tailwind' for Resmed

Resmed has beaten expectations with $2 billion in second-quarter revenue and says weight loss drugs are actually boosting sales, rather than hurting them.

AAP

Is ResMed Stock Underperforming the S&P 500?

Though ResMed has lagged behind the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Barchart

How Is ResMed's Stock Performance Compared to Other Healthcare Stocks?

ResMed has significantly outperformed other healthcare stocks over the past year, and analysts remain bullish on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Resmed Inc (NYSE:RMD) reported better-than-expected earnings for the second quarter on Thursday.

Benzinga

Global demand helps push ResMed shares to record high

ResMed shares have hit an all-time high after the medical device-maker beat expectations on both revenue and profit.

AAP

Are Wall Street Analysts Bullish on ResMed Stock?

Although ResMed has outperformed the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

Solid earnings and tariff break awaken ResMed price

While US President Donald Trump's tariffs have sent global markets into a tailspin, medical technology companies are well-positioned to weather the storm.

AAP

Read news from The Economist, FT, and more,
with one subscription

Earnings Preview: What to Expect From ResMed’s Report

ResMed is set to release its fiscal third-quarter earnings this month, with analysts forecasting a lower-double-digit growth in profits.

Barchart

Is ResMed Stock Outperforming the Dow?

Despite ResMed’s outperformance relative to the Dow Jones over the past year, analysts are cautiously optimistic about the stock’s prospects.

Barchart

The global sleep crisis is costing companies. These 3 things are driving it.

Globally, 71% of employed respondents have called in sick due to poor sleep at least once in their career.

Fortune

ResMed's Quarterly Earnings Preview: What You Need to Know

ResMed is expected to release its fiscal second-quarter earnings this month, and analysts project a double-digit profit growth.

Barchart

Is ResMed Stock Outperforming the Nasdaq?

ResMed has outpaced the broader Nasdaq Composite index over the past year, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

ResMed Stock: Is Wall Street Bullish or Bearish?

Although ResMed has outperformed relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart

Fabric face mask to help apnoea sufferers rest easy

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had been dreaming about for a decade.

AAP

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

ResMed's Q1 2025 Earnings: What to Expect

ResMed is scheduled to report its first-quarter earnings later this month, and analysts project a double-digit rise in its bottom line.

Barchart

Is ResMed Stock Outperforming the S&P 500?

ResMed has recently outperformed the S&P 500, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

ResMed Stock: Analyst Estimates & Ratings

Despite ResMed’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

AAP

Weight-loss drugs not lights out for ResMed: CEO

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Five Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Barchart

After Blowout Earnings, This Dividend Stock Still Looks Cheap

Despite its remarkable post-earnings rally, here's a dividend stock that still carries a bargain tag.

Top News

FDA deems ResMed's respiratory device recall as most severe

Learn about the recent recall of ResMed's respiratory devices by the US FDA, deemed as the most serious. Find out more about the implications and what acti...

AAP

Australians losing sleep over cost of living crisis

Australians should take sleep seriously as a survey marking World Sleep Day sheds light on the impact of financial pressures, experts say.

Tribune News Service

ResMed rings up record $1B in sales in latest quarter led by connected sleep apnea devices

For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of the pandemic.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022

Upgrades

Benzinga

Here's How Much You Would Have Made Owning ResMed Stock In The Last 20 Years

ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 18.75%. Currently, ResMed has a market capitalization of $30.88 billion.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.